Chief Financial Officer
Dominic Piscitelli joined AnaptysBio as Chief Financial Officer in January 2017, with more than 15 years of industry experience. He has experience with commercial product launches (XTANDI® and Tarceva®), marketing partnerships, in-licensing transactions, acquisitions and debt and equity financings. Prior to joining AnaptysBio, Mr. Piscitelli was Vice President of Finance, Strategy and Investor Relations at Medivation, Inc., and played in a key role in their acquisition by Pfizer. Between 2011 and 2012, Mr. Piscitelli served as Senior Director of Collaborations and Operations Finance at Astellas Pharmaceuticals. From 2001 to 2011, Mr. Piscitelli served in various roles of increasing responsibility culminating as the Vice President, Treasury & Management Finance at OSI Pharmaceuticals, and played a significant role in their acquisition by Astellas Pharmaceuticals. Mr. Piscitelli holds a Bachelors in accounting and Masters degree in finance and is a Certified Public Accountant.